Modern Perspectives in Advanced Melanoma

Modern Perspectives in Advanced Melanoma

Episodes

Specialty:

All

Year:

All

EP. 1: The Optimal Approach to Treating Advanced Melanoma

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 2: Impact of MSLT-II Data on Completion Lymph Node Dissection

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 3: Neoadjuvant Melanoma Therapy: Patient Selection

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 4: Importance of Molecular Testing in Stage III Melanoma

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 5: Adjuvant Clinical Trial Data Impact on Treatment Selection

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 6: Adjuvant Therapy in Stage IIIB/IIIC/IIID Melanoma

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 7: Balancing Safety and Efficacy in Adjuvant Therapy

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 8: Short-Term COVID-19 NCCN Recommendations

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 9: BRAF-Wild Type vs Mutated Unresectable Melanoma

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 10: Metastatic Melanoma Long-Term Survival Data

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 11: Long-Term Survival Data in Adjuvant Therapy

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

EP. 12: Emerging Treatments for Advanced Melanoma

ByBrian Gastman, MD, Cleveland Clinic,Evan J. Lipson, MD, Johns Hopkins Medicine

December 14th 2020

Trending on OncLive

FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer

Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial

Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia